Mutations in the lipid transporter ABCA7 are known to elevate the risk of Alzheimer’s disease, but how they do so has been murky. Now, scientists led by Li-Huei Tsai at MIT in Cambridge, Massachusetts ...

Polluted air leaves its mark on the brain. In the September 8 JAMA Neurology, Edward Lee and colleagues at the University of Pennsylvania, Philadelphia, report that two decades of autopsies reveal a ...

Some evidence suggests that regular consumption of fish, nuts, fruits, veggies, and whole grains, aka the Mediterranean diet, reduces a person’s risk of dementia. APOE4, on the other hand, increases ...

Antisense oligonucleotides have emerged as a promising approach for treating neurodegenerative disease. They can dial down toxic proteins or help restore functional ones, and have been approved for ...

The infamous paired helical filaments (PHFs) of tau that sprawl across the brain in Alzheimer’s disease are the end products of a multiyear process. What drives tau to form these specific filaments in ...

Short or tall? Curly hair or straight? DNA holds those answers, but it can also reveal much more. In the September 8 issue of Nature Genetics, scientists led by Aliza and Thomas Wingo at the ...

This interactive resource organizes decades of data on biomarkers for Alzheimer's disease. Biomarker measurements from the cerebrospinal fluid and blood are curated from the primary literature and ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

After two years, half of AD patients taking gantenerumab become amyloid-negative. One-third develop ARIA-E, usually without symptoms. Lilly’s N3pG, directed against pyroglutamate Aβ, clears plaques in ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...